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A high-density immunoblotting 
methodology for quantification 
of total protein levels and 
phosphorylation modifications
F. Mazet, J. L. Dunster, C. I. Jones, S. Vaiyapuri, M. J. Tindall, M. J. Fry & J. M. Gibbins
The components of many signaling pathways have been identified and there is now a need to 
conduct quantitative data-rich temporal experiments for systems biology and modeling approaches 
to better understand pathway dynamics and regulation. Here we present a modified Western 
blotting method that allows the rapid and reproducible quantification and analysis of hundreds of 
data points per day on proteins and their phosphorylation state at individual sites. The approach is 
of particular use where samples show a high degree of sample-to-sample variability such as primary 
cells from multiple donors. We present a case study on the analysis of >800 phosphorylation data 
points from three phosphorylation sites in three signaling proteins over multiple time points from 
platelets isolated from ten donors, demonstrating the technique’s potential to determine kinetic 
and regulatory information from limited cell numbers and to investigate signaling variation within a 
population. We envisage the approach being of use in the analysis of many cellular processes such as 
signaling pathway dynamics to identify regulatory feedback loops and the investigation of potential 
drug/inhibitor responses, using primary cells and tissues, to generate information about how a cell’s 
physiological state changes over time.
Standardised methods for the quantification of proteins and their post-translational modification (PTM) 
are necessary to understand the complex pathways and networks controlling cell biology and physiology. 
This would open up the potential for integration or comparison of data from different studies, greatly 
accelerating the analyses of cell signaling dynamics. Whilst techniques exist to measure and quantify 
PTMs, these are frequently specialist in nature or require a specific design for each protein analysed eg 
ELISA. The future of protein quantification is likely to lie in systematic mass spectrometry quantification 
but this currently requires a high level of technical expertise, is labour and time consuming, and lacks 
the throughput for detailed temporal analysis1–4. Label free mass spectrometry quantification has limita-
tions in that only unique peptides can be assigned unambiguously, hydrophobic protein may be depleted 
during sample preparation, transmembrane proteins often generate few suitable peptides for analysis, 
and high levels of protein modification may interfere with their digestion. Label-free quantification of 
protein phosphorylation is extremely challenging. Whilst mass spectrometry can provide large data sets 
it cannot currently be used for high-density screens at this time5. Enrichment steps are often needed that 
complicate the workflow and problems with digestion efficiency can prevent accurate quantification of 
phosphorylation sites6. All of these technical issues can lead to underestimation and inaccuracies during 
protein quantitation. Antibody-based techniques, including micro-Western array and flow cytometry 
rely on expensive specialised equipment, or kits, and the specificity of protein detection may not be 
assured as the proteins are not individually visualised7–11. This is particularly an issue when examining 
phosphorylation using phospho-specific antibodies as these phosphorylation site motifs can have a high 
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degree of similarity between different phosphoproteins. Importantly, a detailed level of understanding of 
cell signalling requires high-density temporal analyses necessitating large numbers of biological samples, 
a factor difficult to achieve when working with primary cells or tissues. In effect, large scale or routine 
quantification of proteins and PTMs is technically challenging and beyond the reach of many laborato-
ries. This can be seen by the paucity of such data in the literature for most cell systems.
Western blotting is currently used by most laboratories for protein and PTM analysis but these studies 
are usually only semi-quantitative. For example probing with one antibody that recognises the PTM, 
followed by stripping and reprobing with a different antibody that recognises the non-modified protein. 
Both results are then compared to estimate the relative change in protein phosphorylation, but this does 
not give insight into the percentage of protein modified. This method is known to be unreliable since 
the protein and the PTMs can be easily damaged or lost during the stripping treatment. An alternative 
approach consists of comparing equal quantities of the sample of interest blotted onto independent mem-
branes to be probed with different antibodies. However this method assumes that both antibodies bind to 
the protein with a similar affinity. If it is not the case (See Fig. 1 in SI for example) the quantification can 
be under or over-estimated. The final method requires each gel to contain the experimental samples and 
a serial dilution of a known amount of the protein or the peptide corresponding to the PTM to produce 
a standard curve. This approach, whilst appropriate for effective quantification, limits considerably the 
number of samples that can be analysed simultaneously.
Here we describe a simple, rapid and reproducible method that overcomes these technical issues and 
allows the quantification of multiple proteins, or phosphorylation levels of proteins, from a small num-
ber of cells, by adapting and refining commonplace techniques and equipment. Using a series of simple 
modifications to traditional Western blotting protocols, we analysed experimental samples and compared 
the data that were obtained to reference datasets we had generated. To enable the calibration of blotting 
protocols, we incorporated known concentrations of recombinant protein of interest and control proteins 
(IgGs) for comparisons between assays. Using this protocol, one person in a standard laboratory can 
successfully analyse up to 1000 data points in a single day.
Results
Quantification method. Our quantification method is based on the relationship between a known 
concentration of a specific recombinant protein to a quantitative signal emitted by fluorescently-labelled 
antibodies that recognise either the total or the phosphorylated form of the protein. The use of a fluores-
cence detection has the advantage of improved stability of the signal over chemiluminescence, increased 
sensitivity and a broader dynamic range, resulting in more consistent and quantitative measurements.
To calibrate the phosphorylation signal, the phosphorylated protein of interest was first isolated by 
immunopreciptation (IP) using a phosphosite-specific antibody. This step is independent of the source of 
the subsequent experimental samples, which allows the use of any cell lysate and optimal conditions to 
recover the highest possible amount of the phosphorylated protein of interest. The immunoprecipitated 
phosphoprotein was then divided equally in two, and serial dilutions were loaded onto two SDS-PAGE 
gels.
On the first gel, a serial dilution of a known concentration of recombinant protein standard corre-
sponding to each protein under investigation was loaded alongside a standard dilution of an IgG solution 
from the same species as the primary antibody to be used in Western blotting (Fig.  1). The resulting 
blot (Fig. 1, blot A) was probed with an antibody recognising the total protein (i.e. phosphorylated or 
non-phosphorylated), and a fluorescently-labelled secondary antibody that binds to the primary anti-
body and the IgG standard. After scanning with an appropriate imaging system (here we used a Typhoon 
Trio Variable Mode Imager, GE Healthcare), the fluorescence intensities were standardised by normal-
ising them using the fluorescence intensity of the IgG standards. The resulting calibrated values for the 
recombinant protein dilution were then used to plot a standard curve and the number of molecules 
immunoprecipitated (Xip) were determined directly from this (Fig. 1).
The second gel contained only a dilution series of the IPs of the phosphorylated proteins and a stand-
ard dilution of IgGs which may be derived from a different host species to that loaded on gel 1 (Fig. 1). 
The subsequent blot (blot B) was probed with the same phospho-specific antibody used for the immu-
noprecipitation and an appropriate fluorescently-labelled secondary antibody. Since we quantified the 
number of molecules present in this sample with blot A, the role of blot B is to establish the relation-
ships between the total amount of protein loaded and the level of fluorescence signal obtained with the 
phosphosite-specific antibody (Yip).
The results from blots A and B may then be used to quantify any further experimental samples (which 
will usually be whole cell lysates) provided that the blots contain the same standard IgGs as used in 
blot B (Fig. 1c). After normalising the fluorescence intensity values with the IgG values (Z, Fig. 1), the 
concentration of phosphorylated molecules (S) for each sample was then obtained with the following 
calculation: S = (Z/Yip)* Xip. Where the total amount of a given protein needs to be quantified, the nor-
malised florescence intensity of the experimental samples probed with the total antibody may be read 
directly using the recombinant protein standard curve (Fig. 1).
Many technical factors may introduce variations when using immunoblots, including Western blot 
transfer efficiency, secondary antibody affinity, and detection protocols12. Simultaneous detection by the 
secondary antibody of the protein under investigation and the dilutions of control IgG protein ensures 
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Figure 1. Quantification protocol schematic. (A)- Reference dataset schematic: On blot A, a serial dilution 
of the immunoprecipitated phosphorylated protein (IP) was loaded together with a serial dilution of the 
corresponding (non-phosphorylated) recombinant protein and known amounts of IgG. After migration 
of proteins in the gel (schematised on the left) and transfer, the membrane was probed with a primary 
antibody recognising the protein of interest, and subsequently with a fluorescently-labelled secondary 
antibody. An illustrative example for Syk Y525 quantification is shown. In this example, two dilutions of 
an IP using the appropriate phospho-specific antibody (lanes 1, 2) were loaded alongside a serial dilution 
of the corresponding recombinant protein (lanes 3–7) and two dilutions of known amount of rabbit IgGs 
(lanes 8, 9). The recombinant protein also contains a GST tag that increases the molecular weight from 72 
to 100 kDa. The relationship between the amount of immunoprecipitated protein loaded and the amount 
of protein (Xip) was determined from the standard curve shown below the schematic blot. For Blot B, the 
same amounts of IP (lanes 10, 11) were loaded with an IgG serial dilution (lanes 12, 13) on a new gel and 
probed after transfer with the phospho-specific antibody and an appropriate fluorescently-labelled secondary 
antibody. The fluorescence intensity values (Yip) read from this blot were directly related to the amount 
of protein calculated with blot A, and a linear relationship plotted as indicated in the graph. IgG dilutions 
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that experimental results can be accurately compared between separate blots or experiments, with vari-
ations due to technical factors corrected during the analysis.
High-density Western blotting. High-density sample analysis involving the use and simultane-
ous comparison of multiple samples, treatments and time points is crucial to understand molecular 
behavior in cells, although it is frequently overlooked due to practical limitations. When using Western 
blotting methodology, multiplexing using multiple differentially labeled antibodies has become an easy 
way to increase the number of proteins that can be analyzed from a single gel13. Whilst this can work 
well for looking at multiple distinct proteins, as with other antibody-based techniques such as ELISA, 
non-specific binding of the antibodies to other proteins in complex mixture such as cell lysates, repre-
sents a technical hurdle. This is particularly problematic when examining phosphorylated sites within 
proteins, as the kinase substrate recognition sites are usually short and share sequence similarities with 
sites within a single substrate protein or in many different substrate proteins. This means that rapid 
and robust high-density analysis seems beyond the reach of many laboratories. We therefore developed 
a simple workflow that produces reproducible results with sample numbers equivalent to the range of 
assays that can be performed in 384 well plate formats.
We used standard SDS-PAGE mini gels, loaded with experimental samples. In parallel, a number 
of gels, dictated by the size of the experiment, were loaded exclusively with IgG dilutions. Following 
electrophoresis, horizontal strips containing the proteins of interest were cut out and laid onto a piece 
of membrane as indicated in Fig.  2, allowing for the simultaneous transfer of multiple strips14. If the 
proteins of interest are sufficiently different in molecular weight then up to 6 different strips containing 
specific phosphoproteins can be excised from each SDS-PAGE gel.
This system allows direct comparison of samples collected under multiple different test conditions and 
time points, and the simultaneous analysis of different proteins provided that they fall within different 
molecular mass ranges. Strips containing the IgG dilutions were added to each membrane to compare 
with subsequent experiments using the same antibodies. Loading controls (eg. actin) can be performed 
independently or together with one of the strip series.
The transfer of the proteins was performed using standard techniques (in our case by using a semi-dry 
blotter), and membranes were probed using a SNAP i.d. system (Millipore), which reduces dramati-
cally the amount of time necessary for the immunoblotting procedure. The SNAP i.d. 2 blotting system 
allowed us to use membranes that contained up to 13 strips, each with up to 14 experimental samples. 
Thereby, each mini gel membrane can contain up to 182 samples. Finally, we used fluorescently-labelled 
secondary antibodies for detection. The detection procedure for two independent membranes (up to 364 
samples) can then be performed in less than 45 minutes.
Case study. Here we describe a study on human platelets using this technique as an example of pri-
mary cell analysis. One of the challenges with these cells is the inherent variability of platelets that need 
to be isolated freshly for each experiment from human donors. Another is the small sample size that 
can be isolated from individual donors. As a result, most biochemical studies are performed on a small 
number of time points or conditions, with the potential exception of flow cytometry analysis. This tech-
nique, however, relies on the specificity of the antibody for a single protein, which as discussed before, 
can be difficult to achieve with antibodies targeting a small conserved peptide sequence as in the case of 
phospho-specific antibodies. By applying our methods, we are able to analyze dozens of proteins in whole 
cell lysates using a small number of cells, while quantifying the phosphorylation kinetics over detailed 
time courses of several minutes. Given the throughput of our system we can also look at the variability 
between donors and their platelets responses.
Using our method relating the amount of protein in the experimental sample to known amounts of 
the protein under investigation, we estimated the copies per platelet for three proteins from the GPVI 
pathway, Syk, c-Cbl and PLCγ 2, in 4 different donors. The results we obtained were similar with those 
reported for four donors using quantitative mass spectrometry where copy number was estimated by 
using the normalized spectral abundance factor and then correlated to previous copy number measure-
ments on 24 reference proteins15 (See Table S1 in SI). Whilst the values are similar there is still consid-
erable variation observed between individuals, which was not unexpected, that is likely to be influenced 
by a range of both genetic and environmental factors. In both cases the data is presented as copies per 
platelet but this will be influenced by platelet size that is known to vary between individuals and for an 
individual over time. Within our four donors this parameter varied from 6.1–8.7 fl with donors with 
are labelled (p)IgGs on the blot using an antibody recognising the whole protein and (pp)IgGs on blot 
using a phosphosite specific antibody. After checking the ratio of the fluorescence units of the IgG dilutions 
corresponds to the ratio of the amounts loaded (indicated by schematics on the right hand side), IgG were 
used to calibrate the results for further quantification experiments. (B)- Experimental samples: Schematic of 
a gel (left) and resulting blot containing experimental samples and IgG dilutions, probed with the phospho-
specific antibody and fluorescently-labelled secondary antibody. The concentration of the phosphorylated 
protein (S) was calculated after normalisation of the fluorescence values (OD) using the (pp)IgG values.
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larger platelet sizes having higher protein copy numbers. This parameter was not recorded in the mass 
spectrometry study.
Using the same experimental samples we next analysed the phosphorylation state of the same three 
proteins using either the traditional small number of time points or using our high-density workflow for 
western blotting. All three proteins are part of a signaling pathway downstream of the platelet collagen 
receptor, GPVI. Syk and c-Cbl interact, resulting in c-Cbl negatively regulating Syk’s kinase activity. 
PLCγ 2 is downstream of Syk and c-Cbl. All three proteins are known to become phosphorylated at a 
number of specific sites after the activation of GPVI16–21, but the detailed kinetics of these phosphoryl-
ation events were unknown, leaving gaps in the understanding of the their regulation during platelet 
activation.
We used platelets isolated from 10 donors and quantified collagen-related peptide (CRP, a 
GPVI-selective agonist) stimulated phosphorylation of specific sites on Syk, c-Cbl and PLCγ 2 at 10 time 
points and compared the results with that of a traditional approach using 3 donors and 5 time points. In 
both workflows quantification of the results was performed using the protocol described earlier with an 
illustrative reference dataset shown in Fig. 1.
Figure 3 shows the comparison in terms of workload and possible conclusions between the traditional 
immunoblotting protocols and our data rich quantitative system. From a technical viewpoint compared 
to the traditional methodology, while the number of samples analyzed was multiplied by a factor of 20, 
the time and workload of the high-density workflow was substantially reduced. The conclusions drawn 
using the traditional workflow was that although the sites were clearly phosphorylated over time, the 
levels were not statistically different between 30, 60, 90 and 180 seconds in all three cases. In contrast, 
the data rich workflow method demonstrated the dynamics of phosphorylation and dephosphorylation 
over time. For example, the phosphorylation of Syk Y525/Y526 clearly showed a rapid increase upon 
CRP addition, followed by a phase of rapid dephosphorylation of almost half of the molecules. Although 
the dephosphorylation of this site after GPVI activation is known, our kinetic analysis also suggested 
a second, more limited phase of phosphorylation for this site shortly after the first one, suggesting an 
additional regulatory step, which has not been described before. Our data rich method also allows the 
estimation of in vivo rates of phosphorylation. These are not true enzymatic rates but a net value for 
the overall phosphorylation/dephosphorylation at that site. For the Syk Y525 site an initial rate of ~15 
molecules phosphorylated per sec per platelet was estimated from our data. Additional experiments 
could be performed in the presence of kinase or phosphatase inhibitors to dissect the involvement of 
different kinases in the phosphorylation of the site or the contribution of specific phosphatases to its 
dephosphorylation.
Figure 2. High-density western blotting workflow schematic. The three main steps of the procedure are 
illustrated, namely SDS-PAGE electrophoresis followed by multi-strip transfer, and immunoblotting using 
a SNAP i.d. system. The immunoblot shows a typical result for one experimental blot, with 100 samples 
analysed simultaneously and the IgG dilutions in the top right corner of the blot. An estimation of the time 
necessary to obtain two blots is indicated.
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The c-Cbl Y774 site displays a very different kinetic profile, which lacks any fast negative regulatory 
process with the values slowly reaching a steady state over the course of several minutes. This is likely 
due to the recruitment of additional SH2 domain-containing proteins to this site thus protecting it from 
rapid dephosphorylation. Finally the results for PLCγ 2 Y759 show a two-step pattern of phosphorylation 
with very different kinetics to either of the other sites studied here with an initial rapid phase of phospho-
rylation followed by a slower second phase. Some of the different features we observe could have been 
detected with the traditional workflow if using different time points, but due to constraints on feasible 
sample number it would not have been able to detect both rapid changes and long term kinetic trends 
as shown in Fig. 3.
In our example, the standard deviations did not necessarily improve with the use of more platelet 
donors, a fact that is well known in biomedical sciences and illustrates the potential variation that can 
be expected from one subject to another. What the data did allow us to see was the normal variation 
in signaling responses in a normal healthy population. The population variation in signaling responses 
of ten donors is shown by the grey shaded areas in Fig. 3, upper panels, around the population average 
response (dark line). The trend of the kinetics was however conserved in all donors, consistent with their 
importance in the GPVI signaling pathway.
Finally, we looked at the effect of a range of concentrations (0.2, 2 and 5 μ M) of a Syk inhibitor, 
R40622, on the phosphorylation of the same sites in Syk, c-Cbl and PLCγ 2 following stimulation of plate-
lets with the same concentration of CRP as before. It can be seen (See Fig. 2 in SI) that at the low and 
intermediate R406 concentrations when compared to our controls group the phosphorylation response 
is delayed, initial rates are reduced and the maximal phosphorylation obtained is depressed. At later time 
points however the response is still within normal uninhibited range. It is not until the highest dose of 
R406 tested that at all time points the response falls outside normal variations of the signaling response. 
Again if only a small number of time points were sampled this could lead to erroneous conclusions about 
the pathway being completely inhibited when in fact the response is severely delayed. This illustrates that 
when assaying potential therapeutic drugs more detailed analysis of the effects on signaling kinetics are 
needed to fully understand the outcome observed.
Discussion
In this paper, we demonstrate that high-density, temporal data collection and reproducible protein and 
phosphorylation quantification is accessible to most laboratories. When compared to traditional Western 
blotting our workflow is more streamlined and reduces the steps (improving consistency) and the time 
required. The amount of data that can be obtained is in line with more expensive and time-consuming 
methods, hence allowing kinetic analyses or medium scale comparisons of protein regulation. This over-
comes potentially misleading interpretations of more limited kinetic profiles (or commonly encountered 
single data points). Finally, we show that this method can be used for low abundance cells and tissues 
Figure 3. Comparison of typical results obtained with either the high-density workflow or a traditional 
workflow. The number of donors and time points, and average timing for completion of the experiments 
each methodology are indicated on the left panels. For the high-density workflow (upper row), the mean 
number of phosphorylated proteins per platelet from 10 donors and 10 time points (from 0 to 600 seconds) 
are indicated by the dark line and black dots, while the grey area represents the standard deviation. The 
resulting graphs illustrate the phosphorylation kinetics for each site over the course of several minutes as 
well as the extent of the variation that can be expected with primary cells samples. Standard conditions 
for platelet research (n = 3, 5 time points: 0, 30, 60, 90, 180 seconds) were chosen for the traditional 
immunoblotting workflow (bottom row) with mean values of phosphorylated proteins per platelet and 
standard deviations indicated for each time point.
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like primary cancer cells and stem cells that are necessary for the therapeutic translation of basic medical 
and pharmaceutical research.
Methods
Blood was drawn from healthy human donors and informed consent was obtained from all subjects, 
using procedures approved by the University of Reading Ethics Committee and carried out in accord-
ance with the approved guidelines, and collected into 50 ml syringes containing 4% sodium citrate and 
acid citrate dextrose (ACD; 2.5% sodium citrate, 2% D-glucose, 1.5% citric acid). Washed platelets were 
prepared by differential centrifugation as described previously23 and then resuspended in Tyrodes buffer 
containing 0.4 U/ml Apyrase, 1 mM EGTA and 100 μ M Indomethacin to suppress secretion and second-
ary signalling. Platelets were activated using collagen-related peptide (CRP), a GPVI selective agonist 
(provided by Dr Richard Farndale, University of Cambridge, UK), at a final concentration of 10 μ g/ml 
to activate specifically the GPVI receptor, then lysed, denatured and loaded onto 10% SDS-PAGE gels 
(BioRad). Kinase inhibitor R406 was from Selleckchem.
Reference datasets were constructed for each phosphorylated site of interest following platelets treat-
ment with 20 μ M pervanadate24 and activation with 10 μ g/ml CRP for 60 sec (Syk), 90 sec (c-Cbl) and 
5 min (PLCγ 2). The cells were then lysed used RIPA buffer. Each immunoprecipitation was carried out 
using the relevant phosphosite-specific antibody and PureProteome Protein A magnetic beads (Millipore) 
as indicated by the manufacturer.
To quantify the amount of immunoprecipitate obtained for each phosphorylated site, dilutions were 
loaded alongside the corresponding recombinant proteins (Syk, GST-tagged, Abnova; PLCγ 2 His-Tag, 
Calbiochem; c-Cbl proprietary tag, Abcam.) and the relevant IgG dilutions (Rabbit or Murine Isotype 
controls, US Biological). To quantify the level of fluorescence produced by phospho-specific antibodies, 
a second gel was loaded with the same immunoprecipitate dilutions and the relevant IgG dilutions. 
The range of the IgG dilution needs to be assessed prior to the experiments. After migration, the pro-
teins from both gels were transferred to Immobilon-FL membrane (Millipore) using a semi-dry blotter 
(Bio-Rad).
Experimental samples and relevant IgG dilutions were loaded on 10% SDS-PAGE gels (BioRad) 
together with the relevant IgG dilutions. After migration, the gels were cut horizontally in roughly 1 cm 
wide strips guided by the molecular weight marker to isolate the proteins of interest, using a plastic cut-
ter, and each band transferred onto Immobilon-FL membranes, making sure that both membranes and 
strips remained wet at all time during the procedure. IgG dilutions were cut independently and loaded 
onto each membrane. Proteins from the gel strips were then transferred using a semi-dry blotter.
Membranes were blocked with 5% (w/v) BSA and probed as instructed by the manufacturer using 
the SNAP i.d. protein detection system (Millipore) and the appropriate antibodies (Anti-Syk N-19, 
Santa-Cruz Biotechnology Inc; anti-c-Cbl, BD Biosciences; anti-LAT, anti-LAT phospho Y132, anti-Syk 
phospho Y525+ Y526, anti-c-Cbl phospho Y774, anti-PLCγ 2, anti-PLCγ 2 phospho Y759, Abcam). The 
blots were treated with either a Goat anti-Rabbit IgG (H+ L) secondary antibody, Cy5 conjugate, or a 
Donkey anti-mouse IgG secondary antibody, Alexa-Fluor 647 conjugate (Life Technologies).
Digital scan values of the fluorescence emission were obtained using a Typhoon Trio Variable Mode 
Scanner (GE Healthcare Life Sciences). Quantification of the fluorescent signals were performed using 
the ImageQuant TL software. Quantification of the amount of phosphorylated molecule for each specific 
site was calculated using the formula described in Fig. 1 for each experimental sample, after calibration 
using the IgG and checks that the Xip/Yip ratios were consistent for each IP dilutions. Data analyses 
were performed using R25.
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